Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Gross Profit: 2020-2025

Historic Gross Profit for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $95,000.

  • Silence Therapeutics' Gross Profit rose 104.44% to $95,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 319.24%. This contributed to the annual value of $31.4 million for FY2024, which is 67.49% up from last year.
  • Silence Therapeutics' Gross Profit amounted to $95,000 in Q3 2025, which was down 31.65% from $139,000 recorded in Q2 2025.
  • Silence Therapeutics' 5-year Gross Profit high stood at $23.3 million for Q4 2024, and its period low was -$2.6 million during Q2 2024.
  • Over the past 3 years, Silence Therapeutics' median Gross Profit value was $934,587 (recorded in 2023), while the average stood at $4.6 million.
  • Data for Silence Therapeutics' Gross Profit shows a peak YoY increase of 2,389.55% (in 2024) and a maximum YoY decrease of 241.92% (in 2024) over the last 5 years.
  • MRQ analysis of 5 years shows Silence Therapeutics' Gross Profit stood at $1.8 million in 2021, then tumbled by 42.54% to $1.1 million in 2022, then decreased by 12.05% to $934,587 in 2023, then surged by 2,389.55% to $23.3 million in 2024, then crashed by 99.59% to $95,000 in 2025.
  • Its Gross Profit was $95,000 in Q3 2025, compared to $139,000 in Q2 2025 and $88,000 in Q1 2025.